TrialX, a NYC-based life sciences technology company has launched Covid Labs, an open platform made up of computer scientists, informaticians, data scientists and designers that are banding together across organizations to solve unique challenges posed by the COVID-19 pandemic. The initiative aims to enable individuals, healthcare agencies, life sciences companies and governments to leverage the power of data, web and mobile technologies to understand and tackle this global crisis.
Dr. Sharib Khan, Co-founder and CEO of TrialX, who kickstarted this initiative mentioned, “As we face a once in a lifetime pandemic, the speed at which the COVID-19 has spread globally, requires the same agility in how we respond to it. Whether it be social distancing to ‘flatten the curve’, or staying up all night, to hack open data sets or re-package existing code, the crisis is a rallying cry for all of us to pitch in.”
In the spirit of “hacking” the pandemic, the lab has already launched several projects including CovidClinicalTrials.com, a global clinical trials tracker displaying a dashboard of all ongoing/planned COVID clinical trials and new treatments and vaccines being investigated by sponsors and research universities. The website provides resources for patients to find and contact research centers near them. The lab has also created a cross-platform symptom tracker app based on Apple’s ResearchKit and Android ResearchDroid to allow investigators and researchers to launch research studies for tracking symptoms related to COVID-19. To increase awareness, the lab hosted a discussion on living with Covid-19 on the CureTalks online radio show that features leading experts and patient advocates.
The lab has an open invite to individuals with a passion for life sciences, public health, data and technology to leverage their skills to hack this pandemic.
Including Women of Childbearing Age in Clinical Research
March 26th 2024In recognition of International Women's Month, we're featuring this recent talk between Associate Editor Miranda Schmalfuhs and Marie Teil, Global Head of UCB’s Women of Childbearing Age Program. They speak about the specific challenges women with chronic illnesses face when accessing appropriate treatment and participating in clinical trials, UCB's Women of Childbearing Age Program and it’s most successful strategies, and much more.
Improving Engagement While Maintaining Data Integrity & Validity
March 19th 2024In recognition of Women's Health Month, we're featuring this recent talk between Associate Editor Miranda Schmalfuhs and uMotif's Chief Product Officer, Julia Lakeland, discuss new technologies improving patient engagement and reducing the emotional and logistical burdens of participation, ethical considerations that should be addressed when implementing those technologies, while ensuring patient privacy, and much more.
FDA Fast Tracks Johnson & Johnson’s Nipocalimab for Fetal Neonatal Alloimmune Thrombocytopenia
March 27th 2024Johnson & Johnson is moving forward with a pair of Phase III trials of nipocalimab to reduce the risk of fetal neonatal alloimmune thrombocytopenia in alloimmunized pregnant patients.